z-logo
open-access-imgOpen Access
Antigenic Peptides Capable of Inducing Specific Antibodies for Detection of the Major Alterations Found in Type 2B Von Willebrand Disease
Author(s) -
Marina de Oliveira Paro,
Cyntia Silva Ferreira,
Fernanda Silva Vieira,
Marcos Aurélio de Santana,
William CastroBorges,
Maria Sueli Silva Namen-Lopes,
Sophie Leclercq,
Cibele VellosoRodrigues,
Milton Hércules Guerra de Andrade
Publication year - 2013
Publication title -
international journal of peptides
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.239
H-Index - 25
eISSN - 1687-9775
pISSN - 1687-9767
DOI - 10.1155/2013/590329
Subject(s) - von willebrand factor , von willebrand disease , antibody , antigen , immunology , medicine , coagulopathy , disease , monoclonal antibody , platelet
Von Willebrand disease (VWD) is an inherited hemorrhagic disorder promoted by either quantitative or qualitative defects of the von Willebrand factor (VWF). The disease represents the most common human coagulopathy afflicting 1.3% of the population. Qualitative defects are subdivided into four subtypes and classified according to the molecular dysfunction of the VWF. The differential diagnosis of the VWD is a difficult task, relying on a panel of tests aimed to assess the plasma levels and function of the VWF. Here, we propose biochemical approaches for the identification of structural variants of the VWF. A bioinformatic analysis was conducted to design seven peptides among which three were representatives of specific amino acid sequences belonging to normal VWF and four encompassed sequences found in the most common VWD subtype 2B. These peptides were used to immunize mice, after which, peptide-specific immunoglobulins were purified. This resulted in four Ig preparations capable of detecting alterations in the subtype 2B VWD plus additional three antibody fractions targeting the normal VWF. The panel of antibodies could serve many applications among them (1) assessment of VWF: antigen interaction, (2) VWF multimer analysis, and (3) production of monoclonal antibodies against VWF for therapeutic purposes as in thrombotic thrombocytopenic purpura.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom